Featured
-
News
DRUGS | EU Pulls Authorization of Adakveo for Sickle Cell Disease
The decision comes after the Committee on Medicinal Products for Human Use (CHMP) recommended in May 2023 to pull the approval following a review of additional Phase III data. The EC’s decision…
Read More » -
TIF News
NEW SURVEY | Thalassaemia Care Delivery From A Patient Perspective
The survey focuses on capturing the patient perspective on thalassaemia care delivery in various countries. This initiative by TIF aims to gather valuable insights into the experiences and challenges faced…
Read More » -
News
NEWS | WHO Updates Essential Medicines List, Adds New Medicines for Thalassaemia
Until recently, the WHO EML recommended only deferoxamine for iron chelation, limiting patients’ access to other crucial pharmacological alternatives for the effective management of their condition. Since 2019, the Thalassaemia…
Read More » -
News
PUBLICATION | Travel Guidance for Patients and Families
Welcome to ‘Travel Guidance for Patients & Families’, on the newest TIF’s publications! This practical handbook is intended specifically for travelers with thalassaemia, sickle cell disease, and rare anaemias. Our…
Read More » -
News
CALL TO ALL PATIENTS | Your Voice Matters in Research!
Today, we invite you to be an active participant in ensuring that research that takes place is aligned with your specific requirements and challenges. Your firsthand experiences as patients offer…
Read More » -
News
OPINION | Proposed SoHO Legislation Could Transform Blood Sustainability in Europe
In this article, she reflected on the importance of EU’s SoHO Regulation – read TIF’s Position Paper on the Regulation here – proposing updated rules on blood, tissue and cells,…
Read More » -
TIF News
AWARDS | Health Ministry Honours Mr Panos Englezos, TIF’s President
The Health Ministry of Cyprus honoured the outgoing chairman of the National Thalassaemia Committee and President of the Thalassaemia International Federation (TIF), Mr. Panos Englezos, with a prize-giving ceremony. The…
Read More » -
News
GENE THERAPY | FDA Decision on Lovo-cel for SCD Now Expected by Year’s End
The regulatory agency has agreed to review an application from lovo-cel’s developer, Bluebird Bio, requesting the gene therapy’s approval for SCD patients ages 12 and older. Moreover, the FDA has given the application priority…
Read More » -
News
-
Scientific News
NHS to Deliver World-First Blood-Matching Test to Aid Thalassemia and SCD Patients
National Health Services (NHS) of England is likely to introduce the world’s first genotyping blood test which could help ease the suffering of patients with thalassaemia, as donated blood poses…
Read More »